Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 25, 2008

Abraxis BioScience to Reacquire U.S. Rights to Abraxane from AstraZeneca

  • Abraxis BioScience is seeking to re-acquire the exclusive rights to market Abraxane® (paclitaxel protein-bound particles for injectable suspension) in the U.S. from AstraZeneca.

    In April of 2006, AstraZeneca inked a five and a half year copromotion agreement with Abraxis, under which Abraxis received an upfront fee of $200 million.

    “We believe the time has come to further build our commercialization platform for Abraxane in the U.S.,” said Patrick Soon-Shiong, M.D., chairman and CEO of Abraxis BioScience. “We have gained much in our collaboration with AstraZeneca and they have done a commendable job in building market share. ”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »